Matejčikova et al. reported significantly lower serum levels of CXCL8 in MS patients than in controls, and significantly higher CSF levels of CXCL8 in MS patients in comparison to controls, which was positively associated with Q-albumin, a marker of BBB damage [39]. This evidence concerns the gene ALB and myeloid sarcoma.